{"id":136303,"date":"2026-06-30T17:32:34","date_gmt":"2026-06-30T12:02:34","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=136303"},"modified":"2026-06-30T17:32:36","modified_gmt":"2026-06-30T12:02:36","slug":"indoco-remedies-q1-results-fy27","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/indoco-remedies-q1-results-fy27\/","title":{"rendered":"Indoco Remedies Q1 Results FY27: What to Expect"},"content":{"rendered":"<p style=\"border-left: 4px solid #1F4E79; background: #EBF3FB; padding: 10px 16px; font-style: italic;\"><em>Indoco Remedies Q1 Results FY27: Revenue Rs 449 Cr (+2.1% YoY) | PAT Rs -18 Cr (-50.0% YoY). Uniresearch Q1 results preview.<\/em><\/p>\n<p>This<a href=\"https:\/\/univest.in\/user\/stocks\/indoco\/indoco-remedies-ltd-share-price-today\"> Indoco Remedies<\/a> Q1 results preview is based on Screener.in consolidated quarterly financials for the Q1 FY26 base quarter, with the Uniresearch trailing-growth model applied to project the Q1 FY27 estimate. Indoco Remedies reported Revenue of Rs 440 Cr and PAT of Rs -36 Cr in Q1 FY26, forming the base for the Indoco Remedies Q1 Results FY27 forecast of Rs 449 Cr Revenue and Rs -18 Cr PAT. Prepared by Ankit Jaiswal, Senior Research Analyst.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&amp;utm_medium=indoco-q1-results\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/indoco-remedies-q1-results-fy27\/#Indoco_Remedies_Q1_Results_FY27_Uniresearch_Prediction\" title=\"Indoco Remedies Q1 Results FY27: Uniresearch Prediction\">Indoco Remedies Q1 Results FY27: Uniresearch Prediction<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/indoco-remedies-q1-results-fy27\/#Indoco_Remedies_Q1_Results_FY27_Preview_Expectations_Results_Date_and_Latest_News\" title=\"Indoco Remedies Q1 Results FY27 Preview: Expectations, Results Date and Latest News\">Indoco Remedies Q1 Results FY27 Preview: Expectations, Results Date and Latest News<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/indoco-remedies-q1-results-fy27\/#Q4_FY26_Performance_Context_for_the_Indoco_Remedies_Q1_Results_FY27_Preview\" title=\"Q4 FY26 Performance: Context for the Indoco Remedies Q1 Results FY27 Preview\">Q4 FY26 Performance: Context for the Indoco Remedies Q1 Results FY27 Preview<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/indoco-remedies-q1-results-fy27\/#Uniresearch_Estimate_Behind_the_Indoco_Remedies_Q1_Results_FY27_Projection\" title=\"Uniresearch Estimate Behind the Indoco Remedies Q1 Results FY27 Projection\">Uniresearch Estimate Behind the Indoco Remedies Q1 Results FY27 Projection<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/indoco-remedies-q1-results-fy27\/#Indoco_Remedies_Q1_Results_FY27_Expectations_Key_Watchpoints\" title=\"Indoco Remedies Q1 Results FY27 Expectations: Key Watchpoints\">Indoco Remedies Q1 Results FY27 Expectations: Key Watchpoints<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/indoco-remedies-q1-results-fy27\/#Revenue_vs_the_Uniresearch_Estimate\" title=\"Revenue vs the Uniresearch Estimate\">Revenue vs the Uniresearch Estimate<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/indoco-remedies-q1-results-fy27\/#PAT_Margin_Sustainability\" title=\"PAT Margin Sustainability\">PAT Margin Sustainability<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/indoco-remedies-q1-results-fy27\/#Management_Commentary_and_Full-Year_FY27_Guidance\" title=\"Management Commentary and Full-Year FY27 Guidance\">Management Commentary and Full-Year FY27 Guidance<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/indoco-remedies-q1-results-fy27\/#Risks_to_the_Indoco_Remedies_Q1_Results_FY27_Prediction\" title=\"Risks to the Indoco Remedies Q1 Results FY27 Prediction\">Risks to the Indoco Remedies Q1 Results FY27 Prediction<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/indoco-remedies-q1-results-fy27\/#Below-Estimate_Revenue_Growth\" title=\"Below-Estimate Revenue Growth\">Below-Estimate Revenue Growth<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/indoco-remedies-q1-results-fy27\/#PAT_Pressure_from_Costs_or_Provisions\" title=\"PAT Pressure from Costs or Provisions\">PAT Pressure from Costs or Provisions<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/indoco-remedies-q1-results-fy27\/#External_and_Macro_Environment\" title=\"External and Macro Environment\">External and Macro Environment<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/indoco-remedies-q1-results-fy27\/#Indoco_Remedies_Q1_Results_FY26-27_Sector_Growth_Drivers_and_Latest_News\" title=\"Indoco Remedies Q1 Results FY26-27: Sector Growth Drivers and Latest News\">Indoco Remedies Q1 Results FY26-27: Sector Growth Drivers and Latest News<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/indoco-remedies-q1-results-fy27\/#Domestic_Formulation_Growth\" title=\"Domestic Formulation Growth\">Domestic Formulation Growth<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/indoco-remedies-q1-results-fy27\/#Regulated_Market_Export_Pipeline\" title=\"Regulated Market Export Pipeline\">Regulated Market Export Pipeline<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/indoco-remedies-q1-results-fy27\/#Indoco_Remedies_Q1_Results_FY27_What_to_Expect\" title=\"Indoco Remedies Q1 Results FY27: What to Expect\">Indoco Remedies Q1 Results FY27: What to Expect<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/indoco-remedies-q1-results-fy27\/#Frequently_Asked_Questions_on_Indoco_Remedies_Q1_Results_FY27\" title=\"Frequently Asked Questions on Indoco Remedies Q1 Results FY27\">Frequently Asked Questions on Indoco Remedies Q1 Results FY27<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/indoco-remedies-q1-results-fy27\/#What_is_the_Uniresearch_prediction_for_Indoco_Remedies_Q1_Results_FY27\" title=\"What is the Uniresearch prediction for Indoco Remedies Q1 Results FY27?\">What is the Uniresearch prediction for Indoco Remedies Q1 Results FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/indoco-remedies-q1-results-fy27\/#What_are_the_Indoco_Remedies_Q1_Results_FY27_expectations\" title=\"What are the Indoco Remedies Q1 Results FY27 expectations?\">What are the Indoco Remedies Q1 Results FY27 expectations?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/indoco-remedies-q1-results-fy27\/#What_were_the_Q4_FY26_actuals_behind_the_Indoco_Remedies_Q1_Results_FY27_projection\" title=\"What were the Q4 FY26 actuals behind the Indoco Remedies Q1 Results FY27 projection?\">What were the Q4 FY26 actuals behind the Indoco Remedies Q1 Results FY27 projection?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/indoco-remedies-q1-results-fy27\/#How_reliable_is_the_Indoco_Remedies_Q1_Results_FY27_Uniresearch_prediction\" title=\"How reliable is the Indoco Remedies Q1 Results FY27 Uniresearch prediction?\">How reliable is the Indoco Remedies Q1 Results FY27 Uniresearch prediction?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/univest.in\/blogs-2\/indoco-remedies-q1-results-fy27\/#What_base_data_is_used_for_the_Indoco_Remedies_Q1_Results_FY27_Uniresearch_projection\" title=\"What base data is used for the Indoco Remedies Q1 Results FY27 Uniresearch projection?\">What base data is used for the Indoco Remedies Q1 Results FY27 Uniresearch projection?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/univest.in\/blogs-2\/indoco-remedies-q1-results-fy27\/#What_are_the_key_risks_to_the_Indoco_Remedies_Q1_Results_FY27_estimate\" title=\"What are the key risks to the Indoco Remedies Q1 Results FY27 estimate?\">What are the key risks to the Indoco Remedies Q1 Results FY27 estimate?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/univest.in\/blogs-2\/indoco-remedies-q1-results-fy27\/#When_will_Indoco_Remedies_Q1_Results_FY27_results_be_announced\" title=\"When will Indoco Remedies Q1 Results FY27 results be announced?\">When will Indoco Remedies Q1 Results FY27 results be announced?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Indoco_Remedies_Q1_Results_FY27_Uniresearch_Prediction\"><\/span><strong>Indoco Remedies Q1 Results FY27: Uniresearch Prediction<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table style=\"width: 100%; border-collapse: collapse;\">\n<thead>\n<tr style=\"background: #EBF3FB;\">\n<th style=\"border: 1px solid #D0D7E2; padding: 9px 14px; text-align: left;\">Metric<\/th>\n<th style=\"border: 1px solid #D0D7E2; padding: 9px 14px; text-align: right;\">Q1 FY26 Actual<\/th>\n<th style=\"border: 1px solid #D0D7E2; padding: 9px 14px; text-align: right;\">Q1 FY27 Uniresearch Prediction<\/th>\n<th style=\"border: 1px solid #D0D7E2; padding: 9px 14px; text-align: right;\">YoY Change<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #F9F9F9;\">\n<td style=\"border: 1px solid #D0D7E2; padding: 9px 14px;\">Revenue (Rs Cr)<\/td>\n<td style=\"border: 1px solid #D0D7E2; padding: 9px 14px; text-align: right;\">440<\/td>\n<td style=\"border: 1px solid #D0D7E2; padding: 9px 14px; text-align: right;\"><strong>449<\/strong><\/td>\n<td style=\"border: 1px solid #D0D7E2; padding: 9px 14px; text-align: right;\">+2.1%<\/td>\n<\/tr>\n<tr style=\"background: #FFFFFF;\">\n<td style=\"border: 1px solid #D0D7E2; padding: 9px 14px;\">PAT (Rs Cr)<\/td>\n<td style=\"border: 1px solid #D0D7E2; padding: 9px 14px; text-align: right;\">-36<\/td>\n<td style=\"border: 1px solid #D0D7E2; padding: 9px 14px; text-align: right;\"><strong>-18<\/strong><\/td>\n<td style=\"border: 1px solid #D0D7E2; padding: 9px 14px; text-align: right;\">-50.0%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p style=\"font-size: 12px; color: #666;\"><em>Source: Q1 FY26 actuals from Screener.in. Q1 FY27 prediction for Indoco Remedies applies Uniresearch trailing growth rates (Revenue +2.1%, PAT -50.0%) to Q1 FY26 verified actuals.<\/em><\/p>\n<p><a href=\"https:\/\/univest.in\/sebi-registered-investment-advisor-india\"><strong>Univest \u2013 A SEBI-Registered Investment Advisor<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Indoco_Remedies_Q1_Results_FY27_Preview_Expectations_Results_Date_and_Latest_News\"><\/span><strong>Indoco Remedies Q1 Results FY27 Preview: Expectations, Results Date and Latest News<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Indoco Remedies Q1 results expectations for FY27 point to Revenue of Rs 449 Cr (+2.1% YoY) and PAT of Rs -18 Cr (-50.0% YoY), based on the Indoco Remedies Q1 Results FY27 Uniresearch estimate. These Indoco Remedies Q1 results expectations assume the growth trajectory from Q1 FY26 continues into Q1 FY27, supported by sector tailwinds in pharmaceuticals. Investors can use this Indoco Remedies Q1 results preview as a directional reference ahead of the official result declaration.<\/p>\n<p>The Indoco Remedies Q1 results date is not yet officially announced. Typically, Q1 results dates for NSE-listed companies are disclosed via a board meeting notice on the NSE or BSE filing portal, shortly after Q1 FY27 ends. For the latest news on Indoco Remedies Q1 results FY26-27, track the Univest Screener and NSE filing alerts. Once the Indoco Remedies Q1 results date is confirmed, compare actual Indoco Remedies results against this Indoco Remedies Q1 Results FY27 preview.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Q4_FY26_Performance_Context_for_the_Indoco_Remedies_Q1_Results_FY27_Preview\"><\/span><strong>Q4 FY26 Performance: Context for the Indoco Remedies Q1 Results FY27 Preview<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The <a href=\"https:\/\/univest.in\/stocks\/indoco\/indoco-remedies-ltd-share-price-today\">Indoco Remedies<\/a> Q1 Results FY27 preview is anchored on Q4 FY26 consolidated Revenue of Rs 476 Cr and PAT of Rs -24 Cr. These Q4 FY26 actuals, combined with Uniresearch trailing growth estimates, form the basis of the Q1 FY27 Uniresearch projection for Indoco Remedies projection.<\/p>\n<p>The sequential comparison also provides useful context. Q4 FY26 Revenue of Rs 476 Cr reflects year-end cycles that may not repeat equally in Q1 FY27. The more meaningful benchmark is the year-on-year comparison against Q1 FY26 Revenue of Rs 440 Cr, where the Indoco Remedies Q1 results expectations target +2.1% growth.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Uniresearch_Estimate_Behind_the_Indoco_Remedies_Q1_Results_FY27_Projection\"><\/span><strong>Uniresearch Estimate Behind the Indoco Remedies Q1 Results FY27 Projection<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Q1 FY27 prediction for Indoco Remedies is derived from Uniresearch trailing analysis, which estimates Q1 FY27 Revenue growth of +2.1% and PAT growth of -50.0% YoY. These trailing rates are applied to Q1 FY26 actuals to arrive at the projection of Rs 449 Cr Revenue and Rs -18 Cr PAT.<\/p>\n<p>The Q1 FY27 estimation methodology for Indoco Remedies applies full-year FY27 trailing growth rates (+2.1% Revenue, -50.0% PAT) uniformly to Q1 FY26 actuals. This approach assumes the quarterly trajectory broadly mirrors the full-year trend. Treat this Q1 results preview as a directional benchmark, not a guaranteed outcome.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Indoco_Remedies_Q1_Results_FY27_Expectations_Key_Watchpoints\"><\/span><strong>Indoco Remedies Q1 Results FY27 Expectations: Key Watchpoints<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Revenue_vs_the_Uniresearch_Estimate\"><\/span><strong>Revenue vs the Uniresearch Estimate<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Whether Indoco Remedies results deliver Revenue in line with the Rs 449 Cr Q1 FY27 Uniresearch estimate for Indoco Remedies (+2.1% YoY). Q4 FY26 Revenue was Rs 476 Cr.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"PAT_Margin_Sustainability\"><\/span><strong>PAT Margin Sustainability<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>PAT of Rs -18 Cr (-50.0% YoY) is the Q1 FY27 Uniresearch estimate for Indoco Remedies. Q4 FY26 PAT was Rs -24 Cr. Margin stability in Indoco Remedies results signals operating leverage.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Management_Commentary_and_Full-Year_FY27_Guidance\"><\/span><strong>Management Commentary and Full-Year FY27 Guidance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Beyond the headline Indoco Remedies Q1 results, management commentary will be watched for full-year FY27 guidance on revenue trajectory, margin direction, and capital allocation.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Risks_to_the_Indoco_Remedies_Q1_Results_FY27_Prediction\"><\/span><strong>Risks to the Indoco Remedies Q1 Results FY27 Prediction<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Below-Estimate_Revenue_Growth\"><\/span><strong>Below-Estimate Revenue Growth<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>If actual Indoco Remedies Q1 results Revenue underperforms the +2.1% growth target, the Rs 449 Cr Indoco Remedies Q1 Results FY27 prediction would be revised downward.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"PAT_Pressure_from_Costs_or_Provisions\"><\/span><strong>PAT Pressure from Costs or Provisions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>One-time charges, elevated provisions, or margin headwinds could push Indoco Remedies results PAT below Rs -18 Cr in Q1 FY27.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"External_and_Macro_Environment\"><\/span><strong>External and Macro Environment<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Macro risks including commodity price movements, rupee volatility, interest rate changes, and FII\/DII sentiment shifts could create downside risk in Indoco Remedies results even if company-specific execution remains on track.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Indoco_Remedies_Q1_Results_FY26-27_Sector_Growth_Drivers_and_Latest_News\"><\/span><strong>Indoco Remedies Q1 Results FY26-27: Sector Growth Drivers and Latest News<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The latest news on Indoco Remedies Q1 results FY26-27 from a sector perspective shows that pharmaceuticals is navigating the following growth drivers heading into Q1 FY27. Investors tracking Indoco Remedies Q1 results should monitor these sector-level trends.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Domestic_Formulation_Growth\"><\/span><strong>Domestic Formulation Growth<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>India&#8217;s domestic pharma market grows at 8-10% annually, led by chronic therapies.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Regulated_Market_Export_Pipeline\"><\/span><strong>Regulated Market Export Pipeline<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>USFDA-approved facilities and a growing ANDA pipeline offer incremental export revenues.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Indoco_Remedies_Q1_Results_FY27_What_to_Expect\"><\/span><strong>Indoco Remedies Q1 Results FY27: What to Expect<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Q1 FY27 Uniresearch projection of Indoco Remedies Revenue Rs 449 Cr and PAT Rs -18 Cr covers the complete Indoco Remedies Q1 results preview, including expectations, risks, and sector outlook. Track the Indoco Remedies Q1 results date confirmation on the Univest Screener for timely updates.<\/p>\n<p>Once the Indoco Remedies results are declared, compare them against this Uniresearch preview to assess beat, meet, or miss. Access expert research and screener tools on Univest to stay updated.<\/p>\n<p style=\"margin-top: 24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> for live Indoco Remedies Q1 FY27 result alerts.<\/em><\/p>\n<div style=\"background: #CC0000; border-radius: 8px; padding: 16px 20px; margin: 24px 0;\">\n<p style=\"color: #ffffff; font-size: 13px; line-height: 1.7; margin: 0;\"><strong style=\"color: #ffffff;\">Disclaimer:<\/strong> Revenue and PAT actuals sourced from Screener.in consolidated quarterly financial data. Q1 FY27 projections are derived from Uniresearch trailing growth rates applied to Q1 FY26 actuals. These are Uniresearch trailing estimates, not guaranteed outcomes. Investments are subject to market risk. For educational purposes only. SEBI RA INH000013776.<\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions_on_Indoco_Remedies_Q1_Results_FY27\"><\/span><strong>Frequently Asked Questions on Indoco Remedies Q1 Results FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Uniresearch_prediction_for_Indoco_Remedies_Q1_Results_FY27\"><\/span><strong>What is the Uniresearch prediction for Indoco Remedies Q1 Results FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Uniresearch projects Q1 FY27 Revenue for Indoco Remedies at Rs 449 Cr (+2.1% YoY) and PAT at Rs -18 Cr (-50.0% YoY), based on trailing analysis of Q1 FY26 actuals (Revenue Rs 440 Cr, PAT Rs -36 Cr). This estimate is directional, not a guaranteed outcome.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_Indoco_Remedies_Q1_Results_FY27_expectations\"><\/span><strong>What are the Indoco Remedies Q1 Results FY27 expectations?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Indoco Remedies Q1 Results FY27 expectations are Revenue Rs 449 Cr (+2.1% YoY) and PAT Rs -18 Cr (-50.0% YoY), per the Uniresearch trailing-growth estimate. These expectations are based on Q1 FY26 actuals from Screener.in.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_were_the_Q4_FY26_actuals_behind_the_Indoco_Remedies_Q1_Results_FY27_projection\"><\/span><strong>What were the Q4 FY26 actuals behind the Indoco Remedies Q1 Results FY27 projection?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Q4 FY26 consolidated Revenue was Rs 476 Cr and PAT was Rs -24 Cr, serving as the most recent sequential reference for this Indoco Remedies Q1 Results FY27 preview.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_reliable_is_the_Indoco_Remedies_Q1_Results_FY27_Uniresearch_prediction\"><\/span><strong>How reliable is the Indoco Remedies Q1 Results FY27 Uniresearch prediction?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Indoco Remedies Q1 Results FY27 preview is a Uniresearch trailing projection, not a guaranteed outcome. Actual results may differ due to macro conditions, seasonal variation, and company-specific execution. Use the projection as a directional benchmark.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_base_data_is_used_for_the_Indoco_Remedies_Q1_Results_FY27_Uniresearch_projection\"><\/span><strong>What base data is used for the Indoco Remedies Q1 Results FY27 Uniresearch projection?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Indoco Remedies Q1 Results FY27 projection uses Q1 FY26 consolidated actuals (Revenue Rs 440 Cr, PAT Rs -36 Cr) from Screener.in, with trailing growth rates (+2.1% Revenue, -50.0% PAT) applied to derive the estimate.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_key_risks_to_the_Indoco_Remedies_Q1_Results_FY27_estimate\"><\/span><strong>What are the key risks to the Indoco Remedies Q1 Results FY27 estimate?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Key risks to the Indoco Remedies Q1 Results FY27 include usfda regulatory risk, us generic pricing erosion, and broader macro headwinds that could cause actual Indoco Remedies results to undershoot the Uniresearch Q1 results preview.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"When_will_Indoco_Remedies_Q1_Results_FY27_results_be_announced\"><\/span><strong>When will Indoco Remedies Q1 Results FY27 results be announced?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Indoco Remedies Q1 results date has not been officially announced yet. Q1 FY27 results for NSE-listed companies are typically declared shortly after Q1 FY27 ends, with the Indoco Remedies Q1 results date disclosed via a board meeting notice on the NSE or BSE filing portal. Track the latest news on Indoco Remedies Q1 results FY26-27 on the Univest Screener for timely updates.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Indoco Remedies Q1 Results FY27: Revenue Rs 449 Cr, PAT Rs -18 Cr (Uniresearch). Q1 results preview, expectations, results date and sector drivers inside.<\/p>\n","protected":false},"author":35,"featured_media":136328,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[3802],"class_list":["post-136303","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news"],"metadata":{"rank_math_internal_links_processed":["1"],"_edit_lock":["1782820959:28"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["842"],"rank_math_seo_score":["73"],"rank_math_title":["Indoco Remedies Q1 FY27 Results: What to Expect"],"rank_math_description":["Indoco Remedies Q1 Results FY27: Uniresearch projects Revenue Rs 449 Cr, PAT Rs -18 Cr. Q1 results preview, expectations, date and sector outlook."],"rank_math_focus_keyword":["Indoco Remedies Q1"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"],"_thumbnail_id":["136328"],"_edit_last":["28"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["22527"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/06\/Indoco-Remedies-Q1-Results-FY27.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/136303","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/35"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=136303"}],"version-history":[{"count":2,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/136303\/revisions"}],"predecessor-version":[{"id":136330,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/136303\/revisions\/136330"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/136328"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=136303"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=136303"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=136303"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}